Compare
Estrella Immunopharma, Inc. vs BioCardia, Inc. vs Tevogen Inc. vs Eloxx Pharmaceuticals, Inc.
| Latest fiscal year | Estrella Immunopharma, Inc. ESLA | BioCardia, Inc. BCDA | Tevogen Inc. TVGN | Eloxx Pharmaceuticals, Inc. ELOX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | n/a | $0 |
| Revenue growth (YoY) | n/a | -100.0% | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$13.06M | -$8.23M | -$26.28M | -$6.00M |
| EPS (Diluted) | -$0.35 | n/a | -$8.08 | -$0.49 |
| Operating cash flow | -$1.79M | -$7.44M | -$12.33M | -$6.33M |
| Free cash flow | n/a | -$7.44M | -$12.39M | n/a |
| Cash & equivalents | $1.38M | $2.50M | $0 | $4.79M |
| Total assets | $3.18M | $3.41M | $4.38M | $5.27M |
| Total liabilities | $13.54M | $2.52M | $12.62M | $17.18M |
| Shareholders' equity | -$10.37M | $895.0K | -$8.23M | -$11.91M |
| Return on year-end equity | n/a | -919.3% | n/a | n/a |
| Shares outstanding | n/a | 10.76M | 4.02M | 4.79M |
Revenue, most recent five fiscal years
| Fiscal year | Estrella Immunopharma, Inc. | BioCardia, Inc. | Tevogen Inc. | Eloxx Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | n/a | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $58.0K Ended 2024-12-31 | n/a | $6.36M Ended 2024-12-31 |
| 2 years earlier | n/a | $477.0K Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $1.35M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $1.01M Ended 2021-12-31 | n/a | n/a |